Eduovisual
Biostatistics & Population Health
Years of potential life lost (YPLL)
— Formula: YPLL = Σ (reference age − age at death), summed only for deaths occurring before the reference age.
— A death at 25 contributes 50 YPLL (if cutoff = 75); a death at 80 contributes 0 YPLL.
— Question contrasts two causes of death and asks which contributes more premature mortality or which should be prioritized for public health intervention.
— Stem describes a community health officer, ACO quality director, or state health department setting priorities.
— Vignette pits a high-mortality elderly disease (e.g., dementia) against a lower-mortality young-adult disease (e.g., MVCs, opioid overdose) — YPLL favors the latter.
Board pearl: If a question asks "which cause of death contributes most to premature mortality in young adults?" — think YPLL framing, and the answer is almost always unintentional injury / overdose / suicide, not cancer or heart disease, despite the latter dominating crude mortality.
— A county health commissioner is allocating limited prevention dollars between two interventions (e.g., colon cancer screening vs. naloxone distribution) and asks which addresses the greater burden of premature death.
— A hospital ACO is choosing quality metrics; leadership wants to reduce years of life lost in the served population.
— A medical examiner or vital-statistics report lists deaths by age and cause; the question asks which cause yields the highest YPLL.
— An occupational medicine stem compares workplace fatalities (often young workers) vs. chronic occupational disease (older retirees).
— Age at death for each decedent or cohort — this is the single most important variable.
— Reference age (usually stated as 75; sometimes 65 or life expectancy).
— Number of deaths per cause (so you can compute total or rate-based YPLL).
— YPLL rate = (total YPLL / population) × 100,000 — used to compare across populations of different size.
— Age-adjusted YPLL — controls for differing age structures between populations (e.g., Florida vs. Utah).
— YPLL before age 65 vs. before age 75 — the cutoff changes the ranking; younger cutoffs further favor injury/overdose causes.
— Total number of deaths (favors common diseases of old age).
— Case-fatality rate (a measure of disease lethality, not population burden).
— Incidence (new cases, not deaths).
Key distinction: Mortality rate answers "how many die"; YPLL answers "how much life was lost." A question emphasizing the age at which people are dying — especially "dying young" or "before their productive years" — is signaling YPLL, not crude mortality or case-fatality rate.
— Most common US convention: age 75 (CDC, County Health Rankings).
— Historical/alternative: age 65 (emphasizes working-age mortality; favored by older economic analyses).
— Life-expectancy-based cutoff: uses the cohort's expected lifespan, allowing international comparisons.
— Rule: deaths at or after the reference age contribute 0 YPLL.
— Often given as a midpoint of an age band (e.g., deaths in the 15–24 group counted at age 19.5).
— Infant deaths can dominate YPLL because (75 − 0) = 75 years per death.
— Multiply per-death YPLL by number of deaths in that age band, then sum across bands.
— Population at risk, typically expressed per 100,000 persons younger than the reference age.
— 4 MVC deaths at age 25 → 4 × (75 − 25) = 200 YPLL.
— 4 MI deaths at age 70 → 4 × (75 − 70) = 20 YPLL.
— Equal death counts; MVCs cause 10× the premature mortality.
Board pearl: On the test, if you're given a table with age-at-death columns, draw a quick "(75 − age) × deaths" column and sum. The cause with the highest sum is the answer, regardless of which cause had more total deaths. The calculation is mechanical — points are lost from miscounting, not from concept failure.
— Step 1: Define the reference age (use 75 unless the stem says otherwise).
— Step 2: For each death, compute individual YPLL = reference age − age at death, but only if age at death < reference age. Otherwise contribution = 0.
— Step 3: Sum individual YPLLs across all deaths from the cause of interest → total YPLL.
— Step 4 (optional): Divide by population under reference age and multiply by 100,000 → YPLL rate per 100,000.
— Use the midpoint of each band as the age at death.
— Example: deaths in the 25–34 band counted at age 29.5 (some sources use 30).
— Per-death YPLL for that band = 75 − 29.5 = 45.5 years.
— Multiply by deaths in band, repeat for each band, sum.
— Applies a standard population's age distribution (typically the 2000 US Standard Population) so two communities with different age structures can be compared fairly.
— Without age adjustment, a young community (e.g., a college town) will appear to have lower YPLL simply because it has fewer elderly residents — a misleading comparison.
— Subtracting age at death from current year instead of reference age.
— Including deaths after age 75 (they should contribute 0).
— Comparing raw YPLL between populations of different sizes — always use YPLL rate for cross-population comparison.
Step 3 management: If a stem asks you to compare premature mortality between two counties, the correct metric is age-adjusted YPLL rate per 100,000, not total YPLL — total YPLL favors larger and older populations and is not a fair comparator for policy decisions.
— Mortality only. Weights deaths by prematurity. Ignores morbidity and quality of life.
— Strength: simple, intuitive, uses readily available death-certificate data.
— Weakness: arbitrary cutoff; ignores disability; treats all years equally regardless of QoL.
— DALY = YLL + YLD (Years of Life Lost + Years Lived with Disability).
— Captures both mortality and morbidity. One DALY = one healthy year of life lost.
— Used by WHO Global Burden of Disease; preferred for chronic diseases like depression, low back pain, blindness, where mortality alone underestimates impact.
— Used in cost-effectiveness analyses. Years of life weighted by a utility (0–1) reflecting health-related quality of life.
— A drug that adds 5 years at utility 0.6 yields 3 QALYs.
— Common threshold for "cost-effective" in US literature: $50,000–$150,000 per QALY gained.
— Average years a person can expect to live in "full health," subtracting time in poor health.
— Observed/Expected deaths × 100; controls for age structure but addresses mortality risk, not prematurity per se.
— Ranking causes of premature death → YPLL.
— Ranking overall disease burden including disability → DALY.
— Cost-effectiveness of an intervention → QALY ($/QALY).
— Comparing mortality risk between populations → age-adjusted mortality rate or SMR.
Key distinction: YPLL and YLL are nearly synonymous (both = years of life lost to death); DALY adds YLD (disability). A stem invoking "burden of disability" or chronic non-fatal conditions like major depression or osteoarthritis points to DALY, not YPLL.
— Allocating prevention resources across competing causes of death.
— Justifying interventions targeting young populations (vaccinations, injury prevention, perinatal care, suicide prevention, overdose response).
— Communicating the impact of conditions whose crude mortality looks small but whose age distribution is young (e.g., pediatric leukemia, congenital heart disease, drowning).
— Conditions causing major disability without death (stroke survivors, schizophrenia, severe arthritis) — use DALY.
— Determining individual patient prognosis — YPLL is a population metric.
— Comparing cost-effectiveness of interventions — use QALY.
— Geriatric care prioritization — YPLL systematically devalues elderly mortality.
— Tier 1 (highest YPLL): unintentional injuries (especially drug poisoning/overdose and MVCs), malignant neoplasms (esp. lung, breast, colon, leukemia), heart disease, suicide, homicide (in select demographics), perinatal conditions.
— Tier 2: liver disease, diabetes, HIV (regionally), stroke.
— Tier 3 (low YPLL despite high crude mortality): Alzheimer disease, influenza/pneumonia in elderly, chronic kidney disease in late life.
— YPLL highlights racial and socioeconomic disparities more starkly than crude mortality because affected groups die younger. E.g., Black/Indigenous communities have markedly elevated YPLL rates from homicide, maternal mortality, and cardiovascular disease.
Board pearl: When a public health stem says "despite fewer total deaths, this cause has the greatest impact on years of life lost in our community" — the cause is invariably one that strikes the young (overdose, suicide, MVC, perinatal) and the metric being invoked is YPLL.
— Naloxone distribution and medication for opioid use disorder (buprenorphine, methadone) — directly attack the #1 driver of working-age YPLL in the US.
— Seat belt laws, motorcycle helmet laws, graduated driver licensing, DUI enforcement — reduce MVC YPLL.
— Firearm safety counseling and safe storage — reduces suicide and unintentional injury YPLL (note: suicide accounts for ~half of US firearm deaths).
— Means restriction, crisis hotlines (988), screening with PHQ-9 in primary care, treatment of depression.
— Prenatal care, folate supplementation, smoking cessation in pregnancy, immunizations (a single prevented infant death = up to 75 YPLL).
— Safe sleep counseling (SIDS prevention).
— Cervical (start age 21), breast (start 40–50), colorectal (start 45 per USPSTF), lung CT in eligible smokers (start 50). Screening that prevents a cancer death at 55 saves 20 YPLL.
— Statins for elevated ASCVD risk, hypertension control, tobacco cessation — each prevented MI at age 55 saves ~20 YPLL.
— Dementia care, cataract surgery, late-life palliation — large QALY/DALY value, small YPLL value.
Step 3 management: When a county health director with a fixed budget asks where to invest to maximize reduction in YPLL, the answer favors opioid harm reduction, MVC/injury prevention, suicide prevention, and prenatal care over interventions like geriatric polypharmacy review or dementia screening — even though the latter are clinically valuable.
— Uses age-adjusted YPLL rate before age 75 as the single mortality metric in its Length of Life domain.
— Each US county is ranked; high YPLL flags communities for intervention.
— Many objectives explicitly target reductions in premature mortality, with YPLL as the implicit outcome.
— A health system serving a young population with high overdose mortality should track YPLL from drug poisoning as a core metric, not merely 30-day readmissions.
— A system serving primarily Medicare beneficiaries (mostly ≥65) will see less YPLL movement; DALY or QALY-based metrics are more appropriate there.
— YPLL rates stratified by race/ethnicity, sex, and ZIP code reveal upstream inequities. E.g., the Black-White YPLL gap in the US is driven heavily by infant mortality, homicide, and cardiovascular disease in midlife.
— Years of Potential Life Lost from occupational injury is a standard OSHA/NIOSH metric — heavily weighted toward construction, agriculture, mining, fishing.
— OECD reports use YPLL to benchmark national health system performance. The US has higher YPLL than peer nations, driven largely by injury, overdose, firearm, and maternal mortality — not by cancer or cardiovascular care quality.
— Arbitrary cutoff age.
— Ignores morbidity and disability.
— Treats all life-years as equivalent regardless of quality.
— Sensitive to data quality of death certificates (cause-of-death miscoding).
Board pearl: If a stem references County Health Rankings, the underlying mortality metric is age-adjusted YPLL before age 75 per 100,000 — memorize this exact phrasing.
— A stem may bait you toward YPLL when the actual best metric for an elderly population is different.
— Geriatric patients dying at 80 of pneumonia contribute 0 YPLL (under cutoff 75) even though their deaths may represent preventable harm (e.g., poor vaccination, nursing home outbreak).
— Life expectancy at age 65 or at age 75 — captures remaining-life gains from geriatric interventions.
— DALY — captures disability burden from dementia, falls, frailty.
— QALY — preferred for cost-effectiveness of geriatric interventions (e.g., hip fracture prevention, cataract surgery).
— HALE (Healthy Life Expectancy) — focuses on years lived in good health, not just survival.
— End-stage liver disease in patients aged 40–60 (alcohol, hepatitis C, NAFLD/MASH) contributes substantial YPLL — middle-aged deaths from cirrhosis are a growing US trend.
— CKD progressing to ESRD in young adults (diabetes, lupus, polycystic kidney disease, IgA nephropathy) similarly contributes meaningful YPLL.
— In contrast, ESRD presenting at age 80 contributes minimal YPLL.
— Public-health agencies using YPLL alone may underinvest in geriatric care; mixed dashboards (YPLL + DALY + life expectancy at 65) provide a more complete picture.
Key distinction: A death at age 60 from cirrhosis = 15 YPLL; a death at age 85 from Alzheimer disease = 0 YPLL. Both are tragedies, but YPLL prioritizes the former for prevention investment. Don't let this disturb you on the exam — that prioritization is the design intent of the metric.
— One infant death (age 0) contributes up to 75 YPLL with the standard cutoff — the maximum possible per death.
— This is why infant mortality is such a powerful driver of national YPLL rankings; the US underperforms peer OECD nations partly because of higher infant mortality.
— Leading pediatric causes of YPLL: congenital anomalies, prematurity-related conditions, SIDS, unintentional injury (drowning, MVC), and increasingly firearm injury (now the leading cause of death in US children aged 1–19).
— Deaths during pregnancy or within 42 days postpartum, typically in women aged 20–40, each represent 35–55 YPLL.
— US maternal mortality (~22/100,000 live births) is the highest among high-income nations, with stark Black-White disparities. This is a recurring health-policy theme.
— Top YPLL drivers: unintentional injury (overdose, MVC), suicide, homicide. Cancer (especially leukemia, lymphoma, testicular, brain) contributes meaningfully.
— By race/ethnicity: Black Americans have ~30–50% higher YPLL than White Americans, driven by homicide, infant mortality, cardiovascular disease, and maternal mortality.
— By sex: Males have higher YPLL across most causes — injury, overdose, suicide, cardiovascular disease in midlife.
— By geography: Rural counties have higher YPLL from MVC, overdose, suicide, and limited acute-care access; urban counties have higher YPLL from homicide in some regions.
— Indigenous/Native American populations (highest US YPLL rates).
— Homeless populations (life expectancy reduced by 20–30 years).
— Incarcerated and recently released individuals (high overdose YPLL).
Board pearl: A single prevented infant or maternal death saves more YPLL than preventing many elderly cancer deaths — this is the math that justifies aggressive investment in prenatal care, safe-sleep programs, and maternal mortality review committees.
— A city of 1 million will have more total YPLL than a town of 10,000 even if the town is far less healthy. Always compare YPLL rates per 100,000.
— A retirement community will appear to have low YPLL because most deaths occur after 75. Age-adjusted YPLL corrects this.
— Changing the reference age from 75 to 65 dramatically reranks causes. Cancer YPLL drops; injury and suicide YPLL stay nearly the same. Always note the stated cutoff.
— YPLL does not predict an individual patient's prognosis. It is a population-level summary measure only.
— A condition like multiple sclerosis causes huge disability over decades but modest mortality before 75. YPLL underrepresents MS's true burden; DALY captures it better.
— Some ethicists argue YPLL embeds an implicit judgment that younger lives are worth more years. The counterargument: YPLL measures prematurity, not personal worth, and is intended for prevention prioritization, not rationing.
— YPLL is only as good as the cause-of-death data. Misclassification on death certificates (especially for overdose, suicide, and elderly comorbid deaths) distorts YPLL rankings.
— Aggregated national YPLL can mask large subgroup disparities. Stratification is mandatory for equity-focused analysis.
Step 3 management: When asked to critique a public health report using YPLL, key flaws to flag are: (1) no age adjustment, (2) no stratification by race/ethnicity/sex, (3) no companion disability metric, and (4) unstated reference age.
— The question is about premature mortality specifically.
— You are prioritizing prevention of fatal outcomes across causes.
— Stakeholders care most about deaths in the young (e.g., a school district, occupational health, perinatal program).
— Data available are limited to death certificates and population denominators.
— The condition causes major non-fatal disability (depression, anxiety, low back pain, osteoarthritis, blindness, hearing loss, schizophrenia, MS, stroke survivors).
— You need to compare burden across a mix of fatal and non-fatal conditions.
— International or WHO-aligned reporting is expected.
— The question is cost-effectiveness of an intervention or drug.
— A $ / QALY ratio is being computed for coverage decisions, formulary placement, or HTA.
— Patient preferences and utilities are explicitly part of the analysis.
— The population is predominantly elderly and YPLL would underrepresent the impact of interventions.
— Comparing health system performance for geriatric care.
— The question is about risk of death, not years lost.
— Comparing two populations with different age structures, with a focus on overall mortality.
— Comparing observed deaths in a cohort to an expected baseline (e.g., occupational cohort studies).
Board pearl: Build a mental "metric chooser" — YPLL = premature death, DALY = death + disability, QALY = cost-effectiveness, life expectancy = remaining years, SMR = observed/expected deaths. Step 3 questions on summary measures are nearly always solved by matching the stem's emphasis to the right metric from this list.
— Deaths per 100,000 population per year, all ages.
— Heavily influenced by population age structure; favors elderly-disease conditions.
— Use case: simple descriptive statistics.
— Deaths in a specific age band per 100,000 in that band.
— Use case: comparing mortality within a single age stratum across groups.
— Adjusts for age structure using a standard population.
— Use case: comparing mortality risk across populations or over time, controlling for aging.
— Deaths among diagnosed cases ÷ total cases. Measures disease lethality, not population burden.
— High for rabies (~100%), Ebola, untreated meningococcemia.
— Low for influenza, COVID in young adults.
— Deaths from cause X ÷ total deaths. Tells you the share of deaths, not the rate.
— Observed deaths ÷ expected deaths × 100. Used in cohort studies (e.g., occupational exposures, transplant outcomes).
— Similar to YPLL but typically uses standard life expectancy at age of death rather than a fixed cutoff. YLL component of DALY.
— YPLL is uniquely sensitive to age at death and uniquely focused on prematurity.
— Mortality rates don't reward youth; CFR doesn't reflect population burden; proportionate mortality is structure-dependent.
Key distinction: Case-fatality rate answers "if you get the disease, what's your chance of dying?" Mortality rate answers "in this population, how common is death from this disease?" YPLL answers "how much life is lost when this disease kills?" Different denominators, different stories — pick the one that matches the stem's question.
— DALY = YLL + YLD; one DALY = one healthy year lost.
— WHO Global Burden of Disease standard.
— Captures conditions like depression, low back pain, anemia, vision loss that YPLL misses.
— Years × utility weight (0–1). Used in cost-effectiveness analyses.
— $/QALY thresholds: ~$50,000 (historical), $100,000–$150,000 (current US).
— Average years lived in full health. Used to compare overall population health.
— Similar to HALE but specifically excludes years with disability rather than weighting by severity.
— DALY component capturing non-fatal burden. Prevalence × disability weight × duration.
— Patient-reported outcome measures; capture subjective well-being not visible in mortality data.
— America's Health Rankings, County Health Rankings (uses YPLL), Human Development Index (life expectancy is one input).
— Words like "burden," "disability," "quality of life," "lived with" → DALY/QALY/YLD.
— Words like "premature," "early death," "years of life lost," "before age 75" → YPLL.
— Words like "cost-effective," "value," "willingness to pay" → QALY.
— Major depression has modest mortality but enormous disability — its DALY rank is much higher than its YPLL rank.
— Drug overdose has high mortality in young adults — its YPLL rank is very high; its DALY rank is also high but driven differently.
Board pearl: Map each metric to its primary use — YPLL = premature death prioritization, DALY = global burden of disease, QALY = cost-effectiveness, HALE = population health summary. Confusion among these is the most common biostatistics trap on Step 3.
— Naloxone distribution (community, pharmacy, take-home from EDs).
— Buprenorphine initiation in EDs and primary care (no waiver required since 2023).
— Methadone access expansion via opioid treatment programs.
— Syringe service programs to reduce overdose, HIV, and HCV transmission.
— Good Samaritan laws and 911 immunity.
— Seat belt and car seat enforcement; graduated driver licensing; alcohol interlocks; lower speed limits in residential areas; road engineering (roundabouts, protected bike lanes).
— 988 Suicide and Crisis Lifeline access; means restriction (firearm safe-storage counseling, medication packaging limits); PHQ-9 screening; rapid mental health referral; safety planning at ED discharge.
— USPSTF-aligned screening: colorectal at 45, breast at 40–50, cervical at 21, lung CT at 50 (eligible smokers); HPV vaccination at 9–12; tobacco cessation; HBV vaccination.
— Hypertension control to <130/80 in most adults; statins per ASCVD risk; tobacco cessation; diabetes management; aspirin only in select primary prevention candidates (USPSTF 2022 narrowed indications).
— Universal prenatal care access; folate; tobacco/alcohol cessation in pregnancy; safe sleep counseling; immunizations (Tdap, influenza, RSV, COVID per current schedule).
— Medicaid expansion correlates with reduced YPLL; insurance access enables prevention.
Step 3 management: When a quality director asks "what intervention will most reduce our community's YPLL?" pick the intervention that maps to the top YPLL cause in that population — not the most clinically familiar disease. Match the lever to the leading driver.
— Update age-adjusted YPLL rate annually using vital statistics data.
— Compare to prior years and to peer benchmark populations.
— Track by cause, age band, sex, race/ethnicity, geography (ZIP code or census tract).
— Overall age-adjusted YPLL per 100,000 before age 75 — top-line indicator.
— Cause-specific YPLL for the top 5–10 drivers.
— YPLL by demographic subgroup to track disparities.
— Trend slopes — is the metric improving, stable, or worsening?
— A drop in YPLL may reflect fewer young deaths (good) or an aging population (composition artifact). Age adjustment disentangles these.
— A rising YPLL despite stable mortality often signals deaths shifting younger (e.g., overdose epidemic).
— CDC WONDER for US national and state data.
— County Health Rankings for county-level.
— OECD Health at a Glance for international comparison.
— State vital statistics offices for granular local data.
— Translate into accessible terms: "Drug overdoses cost our county more years of life last year than cancer and heart disease combined."
— Use bar charts ranking causes by YPLL alongside crude death counts to show the reframing.
— Pair YPLL trends with PDSA cycles on specific interventions (e.g., post-overdose ED bridge clinics).
— Report YPLL outcomes in community health needs assessments (required for nonprofit hospitals by IRS / ACA every 3 years).
CCS pearl: In a population-health or QI vignette, the right "follow-up" is a scheduled annual review of stratified, age-adjusted YPLL data with the community board, with intervention adjustments tied to causes showing the largest gaps versus benchmarks.
— By design, YPLL values years saved in the young more than years saved in the old. Critics argue this risks age-based rationing.
— Counterpoint: YPLL is a prioritization metric for prevention, not a clinical or resource-allocation rule for individual patients. Bedside care must remain age-neutral.
— YPLL exposes inequities (Black-White gaps, rural disparities) — using it without acting on disparities is itself an ethical failure. Ethical use requires stratified reporting and targeted intervention.
— Misclassification of overdose deaths as "accidental poisoning" or "undetermined" understates YPLL. Mandatory reporting and accurate certification are both legal and ethical duties.
— Mandatory reporting of certain causes of death (homicide, suspicious deaths, occupational fatalities) feeds YPLL data integrity.
— Reportable deaths to the medical examiner/coroner — sudden, unexpected, violent, in custody, occupational, or unattended.
— Maternal mortality review committees (state-level) are legally protected processes that improve maternal YPLL data quality.
— Post-overdose ED discharge without buprenorphine initiation and naloxone provision is now considered a patient safety failure — these patients face high 30-day mortality and contribute disproportionately to YPLL. Ensure warm handoff to OUD treatment, naloxone in hand, and follow-up scheduled within 72 hours.
— Post-psychiatric-hospitalization follow-up within 7 days reduces suicide YPLL.
— When discussing population-level data (e.g., presenting a community's high opioid YPLL to a patient as motivation for treatment), avoid stigma and frame as systemic, not personal failure.
Board pearl: Discharging an opioid-overdose survivor from the ED without naloxone, without buprenorphine consideration, and without a follow-up appointment is a transition-of-care safety failure — and a major modifiable contributor to US YPLL.
— Unintentional injury (overdose, MVC).
— Malignant neoplasms.
— Heart disease.
— Suicide.
— Perinatal conditions.
— Homicide (in select demographics).
Key distinction: YPLL = "Young deaths weighted more." If the stem highlights age at death or prematurity, YPLL is the answer; if it highlights total deaths or risk of dying, look elsewhere.
— "County A reports 200 deaths from cause X (mean age 70) and 100 deaths from cause Y (mean age 30). Using YPLL <75, which contributes more premature mortality?"
— Compute: X = 200 × 5 = 1,000 YPLL; Y = 100 × 45 = 4,500 YPLL. Answer: Y.
— "A health commissioner wants a single metric to prioritize prevention investments addressing premature death. Which is most appropriate?"
— Answer: age-adjusted YPLL rate before age 75.
— "A WHO analyst wants to capture the global burden of major depressive disorder. Which metric is most appropriate?"
— Answer: DALY (because depression's burden is largely disability, not mortality).
— "An insurer is deciding whether to cover a $200,000 cancer therapy that extends life by 2 years at utility 0.5. What metric supports the decision?"
— Answer: $/QALY ($200,000 / 1 QALY = $200,000/QALY — above typical thresholds).
— "Which mortality metric does the County Health Rankings use to score Length of Life?"
— Answer: age-adjusted YPLL rate before age 75 per 100,000.
— "Black-White mortality differences are most starkly highlighted by which metric?"
— Answer: YPLL (because Black mortality occurs disproportionately at younger ages).
— "A county has very high opioid overdose deaths in adults 25–44. What intervention maximally reduces YPLL?"
— Answer: naloxone distribution + buprenorphine access, not statin initiative or dementia screening.
— A health department reports raw YPLL without age adjustment. Critique?
— Answer: needs age adjustment + stratification + companion disability metric.
Board pearl: Recognize the trigger phrases — "premature," "before age 75," "years of life lost," "young deaths" — and reach immediately for YPLL. Recognize "burden," "disability," "lived with" — and reach for DALY.
— Formula and cutoff: YPLL = Σ(75 − age at death) for deaths <75; deaths ≥75 contribute 0; compare populations using age-adjusted YPLL rate per 100,000.
— Metric family map: YPLL = premature death; DALY = death + disability (WHO Global Burden of Disease); QALY = quality-weighted years for cost-effectiveness (US threshold ~$100K–$150K/QALY); HALE = healthy life expectancy; SMR = observed/expected deaths.
— Top US YPLL drivers (current era): unintentional injury (especially drug overdose and MVCs), malignant neoplasms, heart disease, suicide, perinatal conditions, and homicide/firearm injury in specific demographics — with firearm injury now the leading cause of death in US children aged 1–19.
— Action levers that maximally reduce YPLL: naloxone + buprenorphine for OUD, 988 and means restriction for suicide, seat belts/DUI enforcement/graduated licensing for MVCs, USPSTF-aligned cancer screening, prenatal care and safe-sleep counseling, hypertension and tobacco control in midlife.
— Limitations to flag: arbitrary cutoff age, ignores disability and quality of life, sensitive to death-certificate accuracy, can mask disparities without stratification, and systematically undervalues elderly mortality (use DALY/QALY/HALE there).
— Ethics & safety: post-overdose ED discharge without naloxone + buprenorphine + follow-up is a transition-of-care safety failure and a major modifiable driver of US YPLL.
Board pearl: When the stem emphasizes age at death and prematurity, the answer is YPLL — and the highest-impact interventions almost always target injury, overdose, suicide, and perinatal/maternal health, not the diseases with the highest crude mortality.